R. F. Wang and S. A. Rosenberg, Human tumor antigens for cancer vaccine development, Immunol. Rev, vol.170, p.85, 1999.

A. F. Kirkin, K. Dzhandzhugazyan, and J. Zeuthen, Melanoma-associated antigens recognized by cytotoxic T lymphocytes, APMIS, vol.106, p.665, 1998.

M. C. Panelli, J. Wunderlich, J. Jeffries, E. Wang, A. Mixon et al., Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100, J. Immunother, vol.23, p.487, 2000.

R. Lau, F. Wang, G. Jeffery, V. Marty, J. Kuniyoshi et al., Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma, J. Immunother, vol.24, p.66, 2001.

E. Jager, D. Jager, J. Karbach, Y. T. Chen, G. Ritter et al., Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4 ? T lymphocytes of patients with NY-ESO-1-expressing melanoma, J. Exp. Med, vol.191, p.625, 2000.

A. Mackensen, B. Herbst, J. L. Chen, G. Kohler, C. Noppen et al., Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34 ? hematopoietic progenitor cells, Int. J. Cancer, vol.86, p.385, 2000.

S. A. Rosenberg, Y. Zhai, J. C. Yang, D. J. Schwartzentruber, P. Hwu et al., Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens, J. Natl. Cancer Inst, vol.90, p.1894, 1998.

M. L. Salgaller, F. M. Marincola, J. N. Cormier, and S. A. Rosenberg, Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides, Cancer Res, vol.56, p.4749, 1996.

F. Lehmann, M. Marchand, P. Hainaut, P. Pouillart, X. Sastre et al., Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection, Eur. J. Immunol, vol.25, p.340, 1995.

S. Ferrone and F. M. Marincola, Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance, Immunol. Today, vol.16, p.487, 1995.

H. Benlalam, N. Labarriere, B. Linard, L. Derre, E. Diez et al., Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy, Eur. J. Immunol, vol.31, 2001.

M. Mori, P. G. Beatty, M. Graves, K. M. Boucher, and E. L. Milford, HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry, Transplantation, vol.64, p.1017, 1997.

A. Kelly, S. H. Powis, L. A. Kerr, I. Mockridge, T. Elliott et al., Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex, Nature, vol.355, p.641, 1992.

V. Brichard, A. Van-pel, T. Wolfel, C. Wolfel, E. De-plaen et al., The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas, J. Exp. Med, vol.178, p.489, 1993.

B. Seed and A. Aruffo, Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure, Proc. Natl. Acad. Sci, vol.84, p.3365, 1987.

E. De-plaen, C. Lurquin, B. Lethe, P. Van-der-bruggen, V. Brichard et al., Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes, Methods, vol.12, p.125, 1997.

C. Schonbach, M. Ibe, H. Shiga, Y. Takamiya, K. Miwa et al., Fine tuning of peptide binding to HLA-B*3501 molecules by nonanchor residues, J. Immunol, vol.154, p.5951, 1995.

Y. Takamiya, C. Schonbach, K. Nokihara, M. Yamaguchi, S. Ferrone et al., HLA-B*3501-peptide interactions: role of anchor residues of peptides in their binding to HLA-B*3501 molecules, Int. Immunol, vol.6, p.255, 1994.

S. Tourdot, A. Scardino, E. Saloustrou, D. A. Gross, S. Pascolo et al., A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes, Eur. J. Immunol, vol.30, p.3411, 2000.

S. Morel, A. Ooms, A. Van-pel, T. Wolfel, V. G. Brichard et al., A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes, Int. J. Cancer, vol.83, p.755, 1999.

E. S. Schultz, Y. Zhang, R. Knowles, J. Tine, C. Traversari et al., A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes, Tissue Antigens, vol.57, p.103, 2001.

K. Falk, B. O.-rotzschke, D. Grahovac, S. Schendel, G. Stevanovic et al., Peptide motifs of HLA-B35 and -B37 molecules, Immunogenetics, vol.38, p.161, 1993.

D. Valmori, J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard et al., Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues, J. Immunol, vol.160, p.1750, 1998.

C. Castelli, P. Tarsini, A. Mazzocchi, F. Rini, L. Rivoltini et al., Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens, J. Immunol, vol.162, p.1739, 1999.

Y. Kawakami, S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang et al., Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression, J. Immunol, vol.154, p.3961, 1995.

V. Tsai, S. Southwood, J. Sidney, K. Sakaguchi, Y. Kawakami et al., Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells, J. Immunol, vol.158, p.1796, 1997.

C. A. Aarnoudse, P. B. Van-den-doel, B. Heemskerk, and P. I. Schrier, Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1, Int. J. Cancer, vol.82, p.442, 1999.

Y. Kawakami, X. Wang, T. Shofuda, H. Sumimoto, J. Tupesis et al., Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes, J. Immunol, vol.166, p.2871, 2001.

E. Jager, J. Karbach, S. Gnjatic, D. Jager, M. Maeurer et al., Identification of a naturally processed NY-ESO-1 peptide recognized by CD8 ? T cells in the context of HLA-B51, Cancer Immunol, vol.2, p.12, 2002.

S. Gnjatic, Y. Nagata, E. Jager, E. Stockert, S. Shankara et al., Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele, Proc. Natl. Acad. Sci. USA, vol.97, p.10917, 2000.

R. M. Luiten, N. Demotte, J. Tine, and P. Van-der-bruggen, A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules, Tissue Antigens, vol.56, p.77, 2000.